Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
15
Recruiting, industry sponsors, Immunology and inflammation, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed251
15 trials
Showing 1 to 15, recently updated first.
TakedaTakeda (TAK)
NCT06581328 · 200 participants (planned) · Start Mar 27, 2025 · Primary completion May 1, 2027
Drug: Vedolizumab IV; Vedolizumab SC · For: Ulcerative Colitis; Crohn's Disease
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 101 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06857942 · 200 participants (planned) · Start Mar 19, 2025 · Primary completion May 2028
Drug: Tirzepatide · For: Psoriasis; Overweight or Obesity
Sites: Phoenix, Arizona; Fountain Valley, California; Fremont, California · 38 sites in all
- A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)Recruiting
Xian-Janssen Pharmaceutical Ltd.Industry
NCT07310095 · 78 participants (planned) · Start Dec 30, 2025 · Primary completion Sep 15, 2027
Drug: Guselkumab (GUS) · For: Crohn Disease
Sites: Guangzhou, China; Hangzhou, China; Hefei, China · 5 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07654751 · 10 participants (planned) · Start Aug 7, 2026 · Primary completion Aug 31, 2027
Drug: Guselkumab · For: Psoriasis; Colitis, Ulcerative; Crohn Disease and 1 more
Sites: Chapel Hill, North Carolina
Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
NCT05906576 · 30 participants (planned) · Start Sep 21, 2023 · Primary completion Nov 2026
Drug: Infliximab · For: Crohn Disease
Sites: Beijing, China
- Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07663526 · 50 participants (planned) · Start Sep 23, 2026 · Primary completion Dec 2028
Drug: TyboWe® Adalimumab Injection · For: Crohn's Disease
Sites: Fuyang, China; Zhengzhou, China; Zhoukou, China · 7 sites in all
- Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06594068 · 16 participants (planned) · Start Jan 16, 2026 · Primary completion Aug 31, 2027
Drug: Anifrolumab · For: Systemic Lupus Erythematosus
Sites: Las Vegas, Nevada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07564505 · 30 participants (planned) · Start Aug 13, 2026 · Primary completion Mar 2029
Drug: Adalimumab Solution for Injection · For: Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease
Sites: Guangzhou, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06875960 · 35 participants (planned) · Start Feb 24, 2026 · Primary completion Jan 31, 2028
Drug: BMS-986165 · For: Systemic Lupus Erythematosus (SLE); Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Sites: Farmington, Connecticut; New York, New York; Oklahoma City, Oklahoma · 4 sites in all
Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
NCT07141004 · 100 participants (planned) · Start Aug 12, 2025 · Primary completion Jun 5, 2027
Drug: Guselkumab · For: Arthritis, Psoriatic
Sites: Ahmedabad, India; Chandigarh, India; Chennai, India · 11 sites in all
Integrative Skin Science and ResearchIndustry
NCT07560618 · 40 participants (planned) · Start Jul 21, 2026 · Primary completion Aug 2027
Drug: Roflumilast Cream 0.15% · For: ITCH; Atopic Dermatitis
Sites: Sacramento, California
Aurinia Pharmaceuticals Inc.Industry
NCT07611214 · 150 participants (planned) · Start Apr 22, 2026 · Primary completion Mar 2, 2029
Drug: LUPKYNIS; belimumab, obinutuzumab or anifrolumab and 2 more · For: Lupus Nephritis
Sites: La Mesa, California; Los Alamitos, California; Arvada, Colorado · 27 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07663331 · 30 participants (planned) · Start Jul 14, 2026 · Primary completion Feb 2028
Drug: TyboWe® Adalimumab Injection · For: Adult Non-infectious Uveitis
Sites: Tianjin, China
- A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic ArthritisPivotal-lookingRecruiting
CARE ARTHRITIS LTD.Industry
NCT06454188 · 100 participants (planned) · Start Dec 3, 2024 · Primary completion Sep 2028
Drug: Upadacitinib 15 MG [Rinvoq]; Placebo · For: Psoriatic Arthritis; Spondyloarthritis, Axial
Sites: Cleveland, Ohio; Portland, Oregon; Philadelphia, Pennsylvania · 5 sites in all
Bausch Health Americas, Inc.Industry
NCT04314375 · 70 participants (planned) · Start Sep 29, 2023 · Primary completion Dec 2026
Drug: Low Dose Budesonide; High Dose Budesonide and 1 more · For: Ulcerative Colitis
Sites: Garden Grove, California; Indianapolis, Indiana; The Bronx, New York · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.